MARINOMED BIOTECH AG |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.45 EUR | 0.00% |
|
-5.68% | -58.64% |
| 05-22 | Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024 | |
| 05-21 | Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- The company has a low valuation given the cash flows generated by its activity.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company benefits from high valuations in earnings multiples.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -58.64% | 20.94M | - | ||
| +2.87% | 94.22B | A- | ||
| -3.42% | 37.76B | A- | ||
| -13.31% | 32.5B | B- | ||
| +72.62% | 27.75B | A | ||
| -12.47% | 16.13B | C | ||
| -0.67% | 14.19B | B- | ||
| -12.95% | 11.42B | D+ | ||
| +190.36% | 11.06B | D | ||
| -54.07% | 9.09B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MARI Stock
- 93Z Stock
- Ratings Marinomed Biotech AG
